The importance of tumor stem cells in glioblastoma resistance to therapy
| Autor: | Stefano Martellucci, Jessica Fabrizi, Francesca Santilli, Vincenzo Mattei, Simona Delle Monache, Claudio Festuccia, Alessandro Colapietro, Adriano Angelucci |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
cancer stem cells
cell self renewal medicine.medical_treatment glioblastoma stem cells and therapy resistance Review Catalysis Targeted therapy lcsh:Chemistry Inorganic Chemistry Cancer stem cell glioblastoma therapy resistance antineoplastic agents Medicine Physical and Theoretical Chemistry Radical surgery humans lcsh:QH301-705.5 Molecular Biology Survival rate Spectroscopy brain neoplasms drug resistance glioblastoma stem cells business.industry neoplastic stem cells Organic Chemistry glioblastoma biomarkers General Medicine disease susceptibility new drugs in the treatment of glioblastoma stem cells Phenotype Computer Science Applications Radiation therapy animals cell differentiation Antitarget lcsh:Biology (General) lcsh:QD1-999 Drug Resistance Neoplasm signal transduction neoplasm Cancer research Stem cell Cancer stem cells Glioblastoma Glioblastoma stem cells Glioblastoma stem cells and therapy resistance Glioblastoma therapy resistance New drugs in the treatment of glioblastoma stem cells Animals Antineoplastic Agents Biomarkers Brain Neoplasms Cell Differentiation Cell Self Renewal Disease Susceptibility Humans Neoplastic Stem Cells Signal Transduction business |
| Zdroj: | International Journal of Molecular Sciences, Vol 22, Iss 3863, p 3863 (2021) International Journal of Molecular Sciences |
| Popis: | Glioblastoma (GBM) is known to be the most common and lethal primary malignant brain tumor. Therapies against this neoplasia have a high percentage of failure, associated with the survival of self-renewing glioblastoma stem cells (GSCs), which repopulate treated tumors. In addition, despite new radical surgery protocols and the introduction of new anticancer drugs, protocols for treatment, and technical advances in radiotherapy, no significant improvement in the survival rate for GBMs has been realized. Thus, novel antitarget therapies could be used in conjunction with standard radiochemotherapy approaches. Targeted therapy, indeed, may address specific targets that play an essential role in the proliferation, survival, and invasiveness of GBM cells, including numerous molecules involved in signal transduction pathways. Significant cellular heterogeneity and the hierarchy with GSCs showing a therapy-resistant phenotype could explain tumor recurrence and local invasiveness and, therefore, may be a target for new therapies. Therefore, the forced differentiation of GSCs may be a promising new approach in GBM treatment. This article provides an updated review of the current standard and experimental therapies for GBM, as well as an overview of the molecular characteristics of GSCs, the mechanisms that activate resistance to current treatments, and a new antitumor strategy for treating GSCs for use as therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|